Accéder au contenu
Merck
  • A multistage pathway for human prion protein aggregation in vitro: from multimeric seeds to β-oligomers and nonfibrillar structures.

A multistage pathway for human prion protein aggregation in vitro: from multimeric seeds to β-oligomers and nonfibrillar structures.

Journal of the American Chemical Society (2011-05-04)
Kang R Cho, Yu Huang, Shuiliang Yu, Shaoman Yin, Marco Plomp, S Roger Qiu, Rajamani Lakshminarayanan, Janet Moradian-Oldak, Man-Sun Sy, James J De Yoreo
RÉSUMÉ

Aberrant protein aggregation causes numerous neurological diseases including Creutzfeldt-Jakob disease (CJD), but the aggregation mechanisms remain poorly understood. Here, we report AFM results on the formation pathways of β-oligomers and nonfibrillar aggregates from wild-type full-length recombinant human prion protein (WT) and an insertion mutant (10OR) with five additional octapeptide repeats linked to familial CJD. Upon partial denaturing, seeds consisting of 3-4 monomers quickly appeared. Oligomers of ~11-22 monomers then formed through direct interaction of seeds, rather than by subsequent monomer attachment. All larger aggregates formed through association of these β-oligomers. Although both WT and 10OR exhibited identical aggregation mechanisms, the latter oligomerized faster due to lower solubility and, hence, thermodynamic stability. This novel aggregation pathway has implications for prion diseases as well as others caused by protein aggregation.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Immunoglobulin G from human serum, ≥95% (GE)